We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

By LabMedica International staff writers
Posted on 22 Oct 2024

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. More...

In the United States alone, the anticipated number of hip and knee arthroplasties is expected to quadruple within the next 10 to 20 years. PJI impacts over 2% of these patients and has become the leading cause of revision arthroplasty. Rapid and accurate diagnosis of PJI is crucial for ensuring that patients receive the most suitable surgical or antimicrobial treatment plan. Now, a state-of-the-art, high-accuracy point-of-care test is being developed to diagnose PJI in under five minutes.

InfectoTest GmbH (Berlin, Germany) is developing InfectoSynovia, a rapid and high-accuracy test designed to identify PJI in less than five minutes. This test employs an innovative electrochemical analysis technique that requires only a minimal sample of synovial fluid. InfectoSynovia aims to significantly decrease the diagnosis time to under five minutes while providing excellent sensitivity and specificity, using a sample as small as 50 microliters (µl) of synovial fluid.

With InfectoTest's unique electrochemical analysis approach, complemented by software that aids in the precise interpretation of results, InfectoSynovia will be capable of detecting low-grade and culture-negative infections. This groundbreaking technology aims to transform the diagnosis of PJI, addressing an escalating global demand as the prevalence of joint replacements increases with aging populations.

"Our InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection,” said Svetlana Karbysheva, MD, PhD., Managing Director of InfectoTest.

Related Links:
InfectoTest GmbH


New
Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.